Company Name: Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. is engaged in the discovery and development of RNA-targeted therapeutics.  The company’s Phase 3 product candidates include:

  • Nusinersen: Treatment for spinal muscular atrophy (SMA)
  • IONIS-TTR Rx: Treatment for transthyretin amyloidosis
  • Volanesorsen: Treatment for conditions that are associated with elevated triglycerides including familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy (FPL)

Ticker Symbol: IONS (NASDAQ)

Social Media:

Ionis Pharmaceuticals LinkedIn

Ionis Pharmaceuticals Twitter

Headquarters: Carlsbad, CA